K
Kelun-Biotech
China-based corporation with a broad pipeline targeting unmet needs in oncology and other serious diseases
About Kelun-Biotech
Kelun-Biotech is a pioneering biopharmaceutical company specializing in the development of innovative therapies for cancer and autoimmune diseases. Operating in the highly competitive biotechnology sector, Kelun-Biotech leverages its proprietary Antibody-Drug Conjugate (ADC) technology to create targeted treatments that improve patient outcomes. The company's primary clients include healthcare providers, research institutions, and pharmaceutical companies seeking cutting-edge solutions for complex medical conditions. Kelun-Biotech's business model revolves around research and development, clinical trials, and strategic partnerships with industry leaders to bring its products to market. Revenue is generated through licensing agreements, milestone payments, and eventual product sales.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Chengdu, China
- Listing
- IPO 2023
- Open positions
- None listed
- Dealroom signal
- 24.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest Oct 2016
- Capital deployed
- —
- Preferred round
- ACQUISITION
- Links
- Website
Latest news
Press, funding announcements and product moves mentioning Kelun-Biotech.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2025 | $250M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | May 2024 | $0 | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $283M | 0% | −$38M | -13.3% |
| 2025 | $283M | +6.5% | −$38M | -13.3% |
| 2024 | $266M | +25.5% | −$9.5M | -3.6% |
| 2023 | $212M | +91.6% | −$44M | -20.6% |
| 2022 | $111M | +2387.3% | −$49M | -44.4% |
| 2021 | $4.4M | — | −$104M | -2334.8% |
Growth signals
Latest recorded traffic for Kelun-Biotech is 3.3K monthly website visits, up 230% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Hillhouse Capital
Lilly Asia Ventures
Mercer
Sherpa Venture Partners
China Cinda Asset Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kelun-Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kelun-Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.